Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M40,167Revenue (TTM) $M4,860Net Margin (%)18.1Altman Z-Score11.6
Enterprise Value $M39,662EPS (TTM) $7.6Operating Margin %27.4Piotroski F-Score5
P/E(ttm)47.8Beneish M-Score-2.8Pre-tax Margin (%)27.4Higher ROA y-yN
Price/Book8.710-y EBITDA Growth Rate %--Quick Ratio2.2Cash flow > EarningsY
Price/Sales8.75-y EBITDA Growth Rate %--Current Ratio2.6Lower Leverage y-yY
Price/Free Cash Flow44.1y-y EBITDA Growth Rate %8.6ROA % (ttm)14.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)21.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M106ROIC % (ttm)25.9Gross Margin Increase y-yY

Gurus Latest Trades with REGN

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

REGN is held by these investors:



REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BROWN MICHAEL SDirector 2017-03-29Sell1,000$400-7.15view
Sanofi10% Owner 2017-01-11Buy87,298$369.710.45view
BAKER CHARLES ADirector 2016-12-12Sell3,000$392.02-5.26view
RYAN ARTHUR FDirector 2016-11-15Sell2,000$429.34-13.5view
GOLDSTEIN JOSEPH LDirector 2016-11-14Sell2,125$450-17.47view
GOLDSTEIN JOSEPH LDirector 2016-07-29Sell2,125$425-12.61view
Sanofi10% Owner 2016-06-14Buy64,731$363.862.07view
RYAN ARTHUR FDirector 2016-05-24Sell1,000$396.64-6.37view
Van Plew Daniel PEVP & General Mgr Industrial O 2016-05-18Sell4,413$385.77-3.73view
GOLDSTEIN JOSEPH LDirector 2016-04-06Sell2,000$425-12.61view

Quarterly/Annual Reports about REGN:

News about regn:

Articles On GuruFocus.com
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (aliro Apr 25 2017 
Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (aliro Apr 25 2017 
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients Apr 24 2017 
Spiros Segalas Sells American Tower, Biogen, Regeneron, Disney Apr 21 2017 
Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Apr 14 2017 
Regeneron Science Talent Search to Ring The Nasdaq Stock Market Closing Bell Apr 06 2017 
Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Fami Apr 06 2017 
Manning & Napier’s Top 3 New Holdings Jan 26 2017 
A Green Light on Bayer Jan 19 2017 
Largest Insider Trades of the Week Jan 16 2017 

More From Other Websites
Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Apr 26 2017
Will Regeneron’s Revenue Surpass Analysts’ Estimates in 1Q17? Apr 26 2017
Will Amgen's Rivals Pop On Its Cholesterol-Busting Drug? Apr 26 2017
Earnings Preview: What To Expect From Amgen On Wednesday Apr 25 2017
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent®... Apr 25 2017
Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent®... Apr 25 2017
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients... Apr 24 2017
Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales Apr 21 2017
EMA panel recommends nod for Sanofi, Regeneron's arthritis drug Apr 21 2017
Sanofi Genzyme hit with patent lawsuit over new eczema drug Apr 20 2017
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain Apr 17 2017
3 Big Reasons to Be Bullish on Biotech Stocks Apr 16 2017
[$$] As Drug Prices Fall, These Stocks Could Rise Apr 14 2017
Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and... Apr 14 2017
Regeneron Pharmaceuticals, Inc. – Value Analysis (NASDAQ:REGN) : April 12, 2017 Apr 12 2017
How These Biotechs Could Save The Drug Sector In Q1 — Or Not Apr 12 2017
Don't Get Your Hopes Up For Biotech's Q1 Earnings Apr 12 2017
Blog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma Apr 12 2017
Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback Apr 12 2017
Generics Set To Weaken This Drugmaker; Can MS Drugs Save It? Apr 11 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)